---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-309692"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2021-10-28T23:59:59+00:00"
generated_at: "2026-06-28T16:55:57.156451+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma promotes Stephen Hill to COO effective Nov 1, 2021

## Summary
- Stephen Hill promoted from Chief Technical Operations Officer to Chief Operating Officer, effective November 1, 2021.
- Hill joined Lyell in June 2019; prior roles include SVP at AstraZeneca and VP at Amgen.
- New base salary of $485,000 with an annual bonus target of up to 55% of base salary.
- No family relationships with directors or executive officers; no arrangements with other persons.
- Employment is at-will; successor not appointed; no departure of any other officer.

## SEC filing metadata
- accession: 0001193125-21-309692
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2021-10-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312521309692/0001193125-21-309692-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312521309692/d250716d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-309692
- JSON: https://secwatch.observer/filing/0001193125-21-309692.json
- Plain text: https://secwatch.observer/filing/0001193125-21-309692.txt

## Key facts
- Executive change
  Stephen Hill changed role as Chief Operating Officer at Lyell Immunopharma, Inc..
  - Action: promoted
  - Role: Chief Operating Officer
  source text: On October 23, 2021, the compensation committee (the “Compensation Committee) of the board of directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) approved the promotion of Stephen Hill, the Company’s Chief Technical Operations Officer, to the position of Chief Operating Officer, to serve in such position until his successor is appointed or until his earlier resignation or removal. Such promotion will be effective on November 1, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000119312521309692/0001193125-21-309692-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.